FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
Year: 2021
Type: article
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciab904
Authors: Elizabeth O’Shaughnessy, Yuliya Yasinskaya, Cheryl Dixon, Karen Higgins, Jason Moore, Kellie Reynolds, Neil M Ampel, David Angulo, Janis E Blair, Antonino Catanzaro, John N Galgiani, Edward Garvey, Royce Johnson, David J Larwood, Gareth Lewis, Rob Purdie, John H Rex, Lisa F Shubitz, David A Stevens, Stephen J Page, Sunita J Shukla, John J Farley, Sumathi Nambiar
Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research, Office of Infectious Diseases, University of Arizona, Scynexis (United States), Mayo Clinic, Mayo Clinic Hospital, University of California San Diego, Mycovia Pharmaceuticals (United States), Kern Medical Center, F2G (United Kingdom), California Institute for Medical Research, Stanford Medicine, Stanford University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Awards: G1469674300, G7121373404
OpenAlex ID: W3206413960